DCTH Delcath stock news
On August 14, 2026, Delcath Systems Inc. (Nasdaq: DCTH) announced the closing of an underwritten public offering of common stock, raising approximately $10.0 million in gross proceeds. The company intends to utilize the net proceeds to fund the continued commercialization of the HEPZATO KIT, support ongoing clinical trials, and for general corporate purposes. This capital infusion strengthens the company's balance sheet as it scales its treatment center network and pursues further market penetration in the interventional oncology sector.